The researchers hope these compounds “will expand the universe of options for improving mental health.”
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Three clinical trials are underway to find out if these psychedelic compounds can provide relief for patients.
Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.
These creatures have more in common with humans than one might suspect.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
Using psychedelics to treat chronic pain is understudied yet full of potential.
“In the pharmaceutical drug development community, this is what you dream about.”